Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Short Interest Down 14.1% in February

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 8,412,337 shares, a decrease of 14.1% from the January 29th total of 9,793,959 shares. Based on an average trading volume of 2,748,111 shares, the days-to-cover ratio is presently 3.1 days. Currently, 4.3% of the company’s shares are short sold. Currently, 4.3% of the company’s shares are short sold. Based on an average trading volume of 2,748,111 shares, the days-to-cover ratio is presently 3.1 days.

Analysts Set New Price Targets

ZBH has been the topic of a number of analyst reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. William Blair began coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They issued a “market perform” rating for the company. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their target price for the company from $94.00 to $120.00 in a research note on Monday, January 5th. Finally, Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $106.20.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. DV Equities LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at about $25,000. Key Financial Inc increased its stake in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. raised its holdings in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its position in Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares in the last quarter. Finally, Monetary Solutions Ltd acquired a new stake in Zimmer Biomet in the fourth quarter valued at $30,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 1.9%

NYSE:ZBH traded down $1.80 on Thursday, reaching $93.95. The company’s stock had a trading volume of 782,803 shares, compared to its average volume of 2,263,259. The firm has a market cap of $18.38 billion, a price-to-earnings ratio of 26.54, a price-to-earnings-growth ratio of 2.00 and a beta of 0.58. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $114.44. The stock has a 50 day moving average price of $92.00 and a 200 day moving average price of $95.81.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.